Conservative treatment 1. Internal medicine The results of randomized controlled studies cannot prove the effectiveness of LAK cells, TIL cells, and IFN-γ in the treatment of metastatic kidney cancer. Currently IFN-α or (and) IL-2 is the first-line treatment option for metastatic kidney cancer treatment, with an effective rate of about 15%. The efficacy of commonly used chemotherapeutic agents (either alone or in combination) in metastatic kidney cancer cannot be determined, and chemotherapy combined with IFN-α or (and) IL-2 has not shown any advantage. In recent years, chemotherapy based on difluorodeoxycytidine (trade name gemcitabine, Keyselect) has shown some efficacy in metastatic kidney cancer and may also be used as a first-line treatment option. The new drug “Sorafenib” is a multi-target kinase inhibitor targeting vascular endothelial growth factor receptor, with an efficiency of 10-40% in the treatment of metastatic kidney cancer, which is a promising drug. 2.Radiotherapy For patients with recurrence of local tumor bed, regional or distant lymph node metastasis, bone or lung metastasis, palliative radiotherapy can achieve the purpose of relieving pain and improving survival quality. In recent years, stereotactic radiotherapy, three-dimensional conformal radiotherapy and intensity modulated conformal radiotherapy can play a better control role for recurrent or metastatic lesions.